Chimeric Antigen Receptor (CAR)-T Cell Therapy Market to Exhibit an Incredible Growth of USD 5.35 Billion by 2030, Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis

Data Bridge Market Research analyses the growth rate of chimeric antigen receptor (CAR)-T cell therapy in the forecast period 2023-2030. The expected CAGR of the chimeric antigen receptor (CAR)-T cell therapy market is around 11.8% in the mentioned forecast period

| Source: Data Bridge Market Research Data Bridge Market Research

NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research completed a qualitative study titled "Chimeric Antigen Receptor (CAR)-T Cell Therapy Market" with 100+ market data tables, pie charts, graphs, and figures spread across Pages and an easy-to-grasp full analysis. Globalization makes it clear that market research report hold immense importance for the growth of many businesses. The wide-ranging Chimeric Antigen Receptor (CAR)-T Cell Therapy market analysis document proves to be true in this regard and is designed in a way that is anticipated. It’s the demand or necessity of today’s business to do market research before taking any verdict about the products. This is a transparent market report which has been structured with authentic tools and techniques. The market research analysis conducted in the winning Chimeric Antigen Receptor (CAR)-T Cell Therapy business report helps improve products and also decide about the necessary changes to the future products.

While creating Chimeric Antigen Receptor (CAR)-T Cell Therapy market report, customer requirements have been understood well and then one method or combination of many methods are used for further processing. In the report, complex market insights are turned into simpler version with the help of proven tools and techniques and then provided to the clients. A combination of industry insight, practical solutions, talent solutions and latest technology enhances the customer experience while using this market research report. The market studies, market insights and market analysis included in the finest Chimeric Antigen Receptor (CAR)-T Cell Therapy report keeps marketplace clearly into the focus.

Data Bridge Market Research analyses the growth rate of chimeric antigen receptor (CAR)-T cell therapy in the forecast period 2023-2030. The expected CAGR of the chimeric antigen receptor (CAR)-T cell therapy market is around 11.8% in the mentioned forecast period. The market was valued at USD 2.19 billion in 2022 and would grow to USD 5.35 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Obtain a PDF Sample of the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-car-t-cell-therapy-market

Chimeric antigen receptor (CAR)-T cell therapy is a kind of therapy wherein T-cells are taken from the patient with the addition of a special protein receptor on the T-cells that attack cancer cells. This therapy is widely used to treat certain blood cancers and is being studied in treating other types of cancer. Millions of CAR-T cells are grown on a large scale in the laboratory and then given to the patient through an infusion. 

The growing number of cancer cases has been shown to increase the chimeric antigen receptor (CAR)-T cell therapy. According to the International Agency for Research on Cancer (IARC), by 2040, cancer cases would increase by 27.5 million cancer diagnoses globally, and cancer death rates will rise by 16.3 million. Additionally, the rise in product approvals by the U.S. FDA makes the market lucrative for investments by the major market players.

The Global Market Is Analyzed in Depth in the Latest Study. Taking into account the current level of competition and its projected evolution over the next few years.

Rapidly increasing demands, a rise in industrialization, consumer awareness, growing sectors, and technical improvements are fueling the expansion of the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market. Sales and revenue in this sector have increased at an exponential rate. The market's size and growth are both expected to increase thanks to the factors driving the market's expansion over the projected period.

Leading businesses in the worldwide Chimeric Antigen Receptor (CAR)-T Cell Therapy market are investing heavily in R&D in order to build a larger client base and expand their share of the market by reintroducing improved products to consumers. All of the companies' strategy, as well as their financial health, revenue, gross margin, and growth rate, are detailed in the study.

Fundamental Aim of Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Report

In the Chimeric Antigen Receptor (CAR)-T Cell Therapy market, every company has goals, but this report focus in on the most important ones, allowing you to gain insight into the competition, the future of the market, potential new products, and other useful information that can boost your sales significantly.

  • Major alterations to the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market in the near future.
  • Notable Market rivals around the world.
  • The Chimeric Antigen Receptor (CAR)-T Cell Therapy Market's Future Scope and Product Outlook
  • Future-promising emerging markets.
  • The Market Presents Difficult Challenges and Threats.
  • Sales data and profiles of the world's leading Chimeric Antigen Receptor (CAR)-T Cell Therapy players

Recent Developments

  • In 2022, Kite, a Gilead Company, received the U.S.FDA approval of Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients. This therapy is for people suffering from large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
  • In 2022, Bristol-Myers Squibb Company stated that Japan's Ministry of Health, Labour and Welfare approved Abecma (idecabtagene violence), which is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy. It treats adult patients suffering from relapsed or refractory (R/R) multiple myeloma.

Key players operating in the chimeric antigen receptor (CAR)-T cell therapy market include:

  • Autolus Therapeutics (U.K)
  • CARsgen Therapeutics Co.Ltd. (U.K)
  •  Juno Therapeutics, Inc.(U.S)
  • Sorrento Therapeutics, Inc. (U.S)
  • bluebird bio, Inc. (U.S)
  • CELGENE CORPORATION (U.S)
  • Eureka Therapeutics Inc. (U.S)
  •  Avacta Life Sciences Ltd. (U.K)        
  • Calyxt Inc.(France)
  • Celyad Oncology SA (Belgium)
  • Fortress Biotech, Inc (U.S.).
  • IMMUNE THERAPEUTICS, INC (U.S.)
  • Gilead Sciences, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Alaunos Therapeutics, Inc (U.S.).
  • Poseida Therapeutics, Inc. (U.S.)

Download the Complete Research Study Here in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-car-t-cell-therapy-market

The investment made in the study would provide you access to information such as:

  • Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry [Global – Broken-down into regions]
  • Regional level split [North America, Europe, Asia Pacific, South America, Middle East & Africa]
  • Country wise Market Size Split [of important countries with major market share]
  • Market Share and Revenue/Sales by leading players
  • Market Trends – Emerging Technologies/products/start-ups, PESTEL Analysis, SWOT Analysis, Porter’s Five Forces, etc.
  • Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size
  • Market Size by application/industry verticals
  • Market Projections/Forecast

Opportunities for Key Players:

  • Increasing Number of Investments by Major Organizations

Increasing investments in chimeric antigen receptor (CAR-T) cell therapy contribute to market growth. For instance, Blackstone stated that funds managed by Blackstone Life Sciences had committed USD 250 million in 2021 to launch a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company. Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH accompanied this company. Thus, this factor boosts market growth.

  • Growing Cases of Multiple Myeloma

The increasing number of cases of multiple myeloma is expected to witness significant growth. For instance, according to GLOBOCAN 2020, the expected number of new cases for multiple myeloma and immunoproliferative diseases in 2020 was around 176,000, and the number is anticipated to reach 290,000 by the year 2040. As per the same source, in 2021, a person was expected to have a 1 in 117 risks of being diagnosed with multiple myeloma by age 85. Thus, this factor helps in the growth of the market.

Key Market Segments Covered in Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Research

Type

  • Abecma
  • Breyanzi
  • Kymriah
  • Tecartus
  •  Yescarta

Target Antigen

  • CD 19
  • CD 20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • Meso
  • Egfrvlll

Therapeutic Application

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Leukemia
  • Multiple Myeloma
  • Neuroblasts, Breast Cancer
  • Acute Myeloid Leukemia
  • Hepatocellular
  • Carcinoma
  • Colorectal Cancer

Browse More About This Research Report @ https://www.databridgemarketresearch.com/reports/global-car-t-cell-therapy-market

Key Growth Drivers:

  • Increased Prevalence of Cancer

There is a surge in cancer cases globally. The increasing preference for Chimeric antigen receptor (CAR)-T cell therapy amongst healthcare providers suffering from cancer is expected to bolster the market growth. As per the Centers for Disease Control and Prevention (CDCP), in the U.S. in 2019, 1,752,735 new cancer cases were witnessed, and 599,589 people died of cancer. For every 100,000 people, around 439 new cancer cases were recorded, and 146 people died of cancer. The increasing number of cancer cases is letting providers adopt more and more of this therapy due to its multiple benefits, which is expected to boost market growth.

  • Growing Product Approvals Associated with Chimeric antigen receptor (CAR)-T cell therapy

The growing number of approvals is also leading to market growth. For instance, the Janssen Pharmaceutical Companies of Johnson & Johnson reported the U.S.FDA approved CARVYKTI in 2022 for the treatment of adults suffering from relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, which includes an immunomodulatory agent, a proteasome inhibitor,  and an anti-CD38 monoclonal antibody. Thus, this boosts the market growth

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Regional Analysis/Insights:

The major countries covered in the chimeric antigen receptor (CAR)-T cell therapy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the market due to robust research and commercial base. Additionally, the increase in clinical trials being conducted for T-cell therapies will further increase the growth of the region's chimeric antigen receptor (CAR)-T cell therapy market during the forecast period

Asia Pacific is projected to witness huge growth in the market because of the highest number of registered clinical trials associated with the therapies. Additionally, the substantial efforts on government investment and reforms are further estimated to boost the growth of the region's chimeric antigen receptor (CAR)-T cell therapy market in the coming years

This Market Intelligence Report Analyses Some of the Most Crucial Concerns:

  • How will the major segments of this international market develop over the next few years?
  • Who are the major players that will dominate the market in the future?
  • When it comes to this industry, who are the top suppliers and producers?
  • How have the most successful companies in the industry planned for future growth and expansion?
  • In what sectors might we expect to see the greatest increase in demand over the coming years?
  • How many distinct subsets of buyers make up this market?
  • Which regional powerhouse do you foresee as becoming the largest player in the international market?
  • Does a new coronavirus pandemic have any consequences?
  • In what ways are established actors stymied by the entry of newcomers, and how may they be overcome?

Table of Contents:

  1. Introduction
  2. Market Segmentation
  3. Executive Summary
  4. Premium Insights
  5. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Regulations
  6. Market Overview
  7. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, By Type
  8. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, By Target Antigen
  9. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, By Therapeutic Application
  10. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, By Region
  11. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Landscape
  12. SWOT Analyses
  13. Company Profile
  14. Questionnaires
  15. Related Reports

Get the Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-car-t-cell-therapy-market

Explore More Reports:

  • Chimeric Antigen Receptor (CAR)-T Therapy Treatment Market, By Therapeutic Application (Leukemia, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer and Others), Development Processes (Autologous CAR-T Cells, Allogeneic CAR-T Cells, Others), Structure (First Generation CAR-T Cells, Second Generation CAR-T Cells, Third Generation CAR-T Cells, Others), Drugs (Yescarta, Kymriah, Actemra, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-car-t-therapy-treatment-market
  • Chronic Lymphocytic Leukemia Therapeutics Market, By Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-chronic-lymphocytic-leukemia-therapeutics-market
  • Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market , By Age Group (Pediatrics, Adults), Diagnosis (Biopsy & Bone Marrow Aspiration, Complete Blood Count (CBC) & Differential, Presence of Philadelphia Chromosome, Spinal Tap & Cerebrospinal Fluid (CSF) Analysis, Immunophenotyping/Phenotyping, Flow Cytometry, Polymerase Chain Reaction (PCR)), Drug Type (Existing Drugs, Pipeline Drugs), Therapy (Targeted Drugs & Immunotherapy, Chemotherapy, Radiation Therapy, Stem Cell Transplantation, Pipeline), Cell Type (Philadelphia Chromosome, Precursor B-Cell ALL, T-Cell ALL), Route of Administration (Oral, Parenteral), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-acute-lymphocytic-lymphoblastic-leukemia-all-therapeutics-market
  • Lymphocytic Choriomeningitis Market, By Treatment (Anti-Inflammatory Drugs, Others), Diagnosis (Polymerase Chain Reaction (PCR), Antibody Detection, Cerebrospinal Fluid Analysis, Viral Culture, Others), Symptoms (Fever, Sensitivity to Light, Tiredness, Nausea, Headache, Stiff Neck, Loss of Appetite, Muscle Aches, Others), Source of Transmission (Droppings, Urine, Saliva, Blood, Nesting Materials of Infected Rodents), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-lymphocytic-choriomeningitis-market
  • Small Lymphocytic Lymphoma Market, By Symptoms (Painless Swelling in Neck, Armpit, or Groin, Fever, Fatigue, Night Sweats, Weight Loss, Loss of Appetite), Diagnosis (Physical Exam, Blood Tests, Imaging Studies, Immunophenotyping, Biopsy), Treatment (Chemotherapy, Targeted Therapy, Stem Cell Transplant, Monoclonal Antibody Therapy, Others), Dosage (Tablet, Capsule, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) https://www.databridgemarketresearch.com/reports/global-small-lymphocytic-lymphoma-market
  • Radiotherapy Market, By Type (Product, Service), Technology (External-Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiotherapy/ Radiopharmaceuticals, Others), Application (External Beam Radiotherapy, Internal Beam Radiotherapy), Procedure (External Beam Radiotherapy, Internal Beam Radiotherapy/Brachytherapy, Systemic, Oral, Intravenous, Instillation Radiotherapy), End User (Hospitals, Radiation Therapy Centers, Specialty Clinics, Others), Distribution Channel (Direct Tender, Retail Sales, Others) https://www.databridgemarketresearch.com/reports/global-radiotherapy-market
  • Oxygen Therapy Equipment Market, By Product Type (Bag-Valve Mask, Oxygen Source Equipment), Portability (Portable, Stationary), Application (Asthma, Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), Respiratory Distress Syndrome, Cystic Fibrosis, Others), End User (Hospitals and Clinics, Ambulatory Surgical Center, Home Care Settings, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-oxygen-therapy-equipment-market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com


Tags

Chimeric Antigen Receptor CAR-T Cell Therapy Market CAR-T Cell Therapy Cell Therapy Market CAR-T Cell Therapy Market size

Related Links